Drugs /

pyrotinib

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells. EGFR and HER2 are receptor tyrosine kinases that are upregulated in various tumor cell types and play major roles in tumor cell proliferation and tumor vascularization.

Clinical Trials

View Clinical Trials for pyrotinib

Pyrotinib has been investigated in 12 clinical trials, of which 11 are open and 1 is closed. Of the trials investigating pyrotinib, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 7 are phase 2 (7 open), and 1 is phase 3 (1 open).

HER2 Overexpression, ERBB2 Amplification, and HER2 Positive are the most frequent biomarker inclusion criteria for pyrotinib clinical trials.

Breast carcinoma, non-small cell lung carcinoma, and malignant solid tumor are the most common diseases being investigated in pyrotinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pyrotinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pyrotinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pyrotinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
shr1258
Drug Target(s) [2]:
EGFR, ERBB2
NCIT ID [1]:
C111895

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.